Rituximab for the treatment of immune checkpoint inhibitor–induced glomerulonephritis
Use of Rituximab in treatment of ICI-induced GN is an attractive option to reduce steroids exposure allowing continued ICI treatment for overall improved renal outcome. Clinical trials to evaluate these findings are needed.
Authors
- Omar Mamlouk (ORCID: https://orcid.org/0000-0002-1242-2740)
- Amanda Tchakarov (ORCID: https://orcid.org/0000-0001-6281-7786)
- Naszrin Arani
- Abhijat Kitchlu (ORCID: https://orcid.org/0000-0002-4340-5046)
- Ala Abudayyeh (ORCID: https://orcid.org/0000-0002-5813-6299)
- Clark R. Andersen (ORCID: https://orcid.org/0000-0003-1846-9117)
- Valda D. Page
- Yimin Geng
- Javier Blanco García (ORCID: https://orcid.org/0009-0005-8174-7871)
- Yazen Alasadi
Institutions
- University Health Network (CA)
- The University of Texas MD Anderson Cancer Center (US)
- University of Toronto (CA)
- The University of Texas Health Science Center (US)
Publication Details
- Journal
- Clinical Kidney Journal
- Published
- 2025-11-29
- DOI
- https://doi.org/10.1093/ckj/sfaf373
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health
- University of Texas MD Anderson Cancer Center